Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company's continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 … [Read More...] about Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
European court rules in favor of Abbott in Dexcom CGM patent spat
The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim from Dexcom (Nasdaq:DXCM). Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space. They offer market-leading … [Read More...] about European court rules in favor of Abbott in Dexcom CGM patent spat
Tandem makes t:slim X2 insulin pump available with Dexcom G7 in Canada
Tandem Diabetes Care (Nasdaq:TNDM) announced today that t:slim X2 insulin pump users in Canada can now access full compatibility with Dexcom (Nasdaq:DXCM) CGMs. Following authorization from Health Canada, in-warranty pump users can access full … [Read More...] about Tandem makes t:slim X2 insulin pump available with Dexcom G7 in Canada
Senseonics highlights early success with Eversense 365 launch
Senseonics (NYSE:SENS) today announced significant progress with the launch of its Eversense 365 continuous glucose monitor (CGM). In September, the company won FDA clearance for the Eversense 365 one-year implantable CGM. With the clearance, it … [Read More...] about Senseonics highlights early success with Eversense 365 launch
Insulet prevails in IP battle with patch pump maker EOFlow
Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court. Both companies develop automated insulin delivery systems utilizing patch pump technology. Insulet offers the … [Read More...] about Insulet prevails in IP battle with patch pump maker EOFlow
Embecta to lay off 118 in Massachusetts following patch pump program discontinuation
Embecta (Nasdaq:EMBC) filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. The state received Embecta's Worker Adjustment and Retraining Notification (WARN) submission on Nov. 26 — the same day it … [Read More...] about Embecta to lay off 118 in Massachusetts following patch pump program discontinuation
Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company's continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 … [Read More...] about Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Modular Medical brings in $8.2M
Modular Medical (Nasdaq:MODD) announced recently that it priced an underwritten public offering worth proceeds of around $8.2 million. The San Diego-based insulin pump maker intends to offer more than 5.45 million shares of its common stock at … [Read More...] about Modular Medical brings in $8.2M
Embecta discontinues insulin patch pump program, plans restructuring
Embecta (Nasdaq:EMBC) announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan. Shares of EMBC ticked up 4.3% to $14.41 apiece before hours after the company announced the discontinuation as … [Read More...] about Embecta discontinues insulin patch pump program, plans restructuring
Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed amount. Intera Oncology develops the Intera 3000 hepatic artery infusion pump and floxuridine, a chemotherapy drug. Both … [Read More...] about Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
Medtronic wins FDA nod for new InPen app to support launch with Simplera CGM
Medtronic (NYSE:MDT) announced today that it received FDA clearance for its new InPen insulin delivery system application. The app features missed meal dose detection and paves the way for the launch of the company's smart multiple daily injection … [Read More...] about Medtronic wins FDA nod for new InPen app to support launch with Simplera CGM
In case you missed it
- Insulet Omnipod 5 is now compatible with Abbott FreeStyle Libre 2 Plus in the U.S.
- Dexcom invests $75M in Oura as companies strike health monitoring partnership
- Medtronic to submit MiniMed 780G to FDA for type 2 diabetes in 2025, updates on patch pump
- Abbott opens new FreeStyle Libre manufacturing plant in Ireland
- The biggest diabetes tech stories of the year so far
- What diabetes tech companies are doing on World Diabetes Day 2024
- Dexcom highlights diabetes awareness with global star power
- Beta Bionics raises $60M Series E to support iLet bionic pancreas
- Avanos Medical earns Medicare win for infusion pump tech
- Senseonics reports mixed Q3 results, positive Eversense 365 outlook
- Insulet stock rises on Q3 beat, raised sales guidance
- Tandem stock rises on 31% Q3 sales growth, raised guidance
- Insulin pump maker PharmaSens adds former ADA leaders, medtech veterans to board
- Abbott reports sustained benefits with Esprit drug-eluting stent
- R3 Vascular wins FDA IDE for drug-eluting scaffold
Clinical Trials
Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks. Unlike traditional CGMs that measure glucose […]
Abbott reports sustained benefits with Esprit drug-eluting stent
Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent. The everolimus-eluting resorbable scaffold system treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. The first-of-its-kind stent provides support to the vessel […]
Elixir Medical has positive data for drug-eluting bioadaptive implant
Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute […]
Luna Diabetes launches trial for ‘world’s smallest insulin patch pump’
Luna Diabetes announced that it launched its pivotal trial for Luna, the company’s miniature automated insulin delivery system. The company describes the system — designed to transform nighttime glucose management — as the world’s smallest patch pump. Luna delivers micro-doses of insulin while the user sleeps. According to the company, it offers the “simplest onboarding […]
SpyGlass Pharma shares positive data for drug-eluting intraocular lens
SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the IOL implant at the time of cataract surgery. The company reported a consistent sustained reduction of intraocular pressure (IOP) across all […]
